Context Therapeutics Inc. (CNTX)
NASDAQ: CNTX · Real-Time Price · USD
0.4670
+0.0012 (0.26%)
Aug 12, 2026, 11:53 AM EDT - Market open

Context Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
8.627.857.227.297.793.63
Research & Development
40.1131.8622.717.787.596.89
Total Operating Expenses
48.7339.729.9225.0715.3810.53
Operating Income
-48.73-39.7-29.92-25.07-15.38-10.53
Interest Income
2.463.383.21.160.55-
Interest Expense
------0.06
Other Non-Operating Income (Expense)
0.310.2-0-0.06-00.13
Total Non-Operating Income (Expense)
2.773.583.21.110.550.07
Pretax Income
-45.96-36.12-26.73-23.96-14.84-10.46
Net Income
-45.96-36.12-26.73-23.96-14.84-10.46
Net Income to Common
-45.96-36.12-26.73-23.96-14.84-10.46
Net Income Growth
------
Shares Outstanding (Basic)
95955816163
Shares Outstanding (Diluted)
95955816163
Shares Change
7.92%62.94%265.88%-463.44%37.90%
EPS (Basic)
-0.48-0.38-0.46-1.50-0.93-3.69
EPS (Diluted)
-0.48-0.38-0.46-1.50-0.93-3.69
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-34.03-26.42-14.56-21.05-13.59-8.8
Free Cash Flow Growth
------
Free Cash Flow Per Share
-0.36-0.28-0.25-1.32-0.85-3.11
EBITDA
-48.71-39.69-29.91-25.06-15.37-10.53
EBIT
-48.73-39.7-29.92-25.07-15.38-10.53
SEC Filings: 10-K · 10-Q